, Question 1
Which statement best characterizes the structural basis for aztreonam's lack of
cross-reactivity in severe penicillin allergy while retaining gram-negative
activity?
A. Its beta-lactam ring is fused to a dihydrothiazine ring, unlike
penicillins.
B. It is a monobactam with a monocyclic beta-lactam nucleus and unique
side chains that avoid IgE recognition.
C. It lacks a beta-lactam ring entirely, so it cannot act as a hapten.
D. It is a carbapenem with a trans-configured hydroxyethyl side chain
that blocks beta-lactamase.
Correct Answer: B - It is a monobactam with a monocyclic
beta-lactam nucleus and unique side chains that avoid IgE
recognition.
RATIONALE
Aztreonam is a monobactam with a monocyclic beta-lactam ring and
distinct R-groups, minimizing cross-reactivity with penicillin IgE.
Option A describes cephalosporins (dihydrothiazine ring). Option C is
false; aztreonam has a beta-lactam ring. Option D describes
carbapenems' resistance mechanism, not aztreonam.
Question 2
A patient with a documented severe cephalosporin allergy (anaphylaxis to
ceftriaxone) requires empiric coverage for a complicated intra-abdominal
infection. Which regimen is most appropriate?
A. Cefepime plus metronidazole
B. Meropenem
C. Aztreonam plus metronidazole
D. Ceftazidime-avibactam
Correct Answer: C - Aztreonam plus metronidazole
Page 2
, RATIONALE
Aztreonam plus metronidazole provides gram-negative and anaerobic
coverage without cross-reactivity risk in severe cephalosporin allergy.
Cefepime and ceftazidime-avibactam are cephalosporins and
contraindicated. Meropenem, though structurally distinct, carries a
small cross-reactivity risk and is often avoided when a safe alternative
exists.
Question 3
Which pharmacodynamic parameter best predicts the efficacy of meropenem,
and how should dosing be adjusted to optimize it?
A. Peak concentration/MIC; give as a single large dose.
B. Time above MIC; use prolonged or continuous infusion.
C. AUC/MIC; use once-daily dosing.
D. Post-antibiotic effect; dose every 48 hours.
Correct Answer: B - Time above MIC; use prolonged or
continuous infusion.
RATIONALE
Carbapenems exhibit time-dependent killing, so the percentage of time
free drug exceeds MIC (%fT>MIC) correlates with efficacy;
prolonged/continuous infusion maximizes this. Option A describes
concentration-dependent killing (e.g., aminoglycosides). Option C
describes vancomycin dosing. Option D is not a primary PD parameter
for carbapenems.
Question 4
A patient receiving IV vancomycin develops flushing, pruritus, and
hypotension within 30 minutes of infusion start. Which mechanism best
explains this reaction?
A. IgE-mediated type I hypersensitivity
B. Direct mast cell degranulation (non-immune)
Page 3
, C. Immune complex deposition (type III)
D. T-cell mediated delayed hypersensitivity (type IV)
Correct Answer: B - Direct mast cell degranulation (non-immune)
RATIONALE
Vancomycin infusion reaction (formerly 'red man syndrome') is caused
by direct, non-immune mast cell degranulation and histamine release,
often rate-related. Type I IgE reactions are less common and typically
require prior sensitization. Type III and IV are not consistent with this
acute, infusion-related presentation.
Question 5
Which statement accurately distinguishes the activity of ceftazidime-avibactam
from that of meropenem against Klebsiella pneumoniae carbapenemase
(KPC)-producing organisms?
A. Meropenem is preferred because KPC enzymes do not hydrolyze
carbapenems.
B. Ceftazidime-avibactam is active because avibactam inhibits KPC,
whereas meropenem is hydrolyzed.
C. Both agents are equally active; choice depends only on allergy history.
D. Ceftazidime-avibactam is inactive against KPC; only colistin retains
activity.
Correct Answer: B - Ceftazidime-avibactam is active because
avibactam inhibits KPC, whereas meropenem is hydrolyzed.
RATIONALE
Avibactam is a diazabicyclooctane beta-lactamase inhibitor that
inhibits KPC and other serine carbapenemases, restoring ceftazidime
activity. Meropenem is hydrolyzed by KPC. Option A is false; KPC
hydrolyzes carbapenems. Option C is incorrect because activity
differs. Option D is outdated; newer agents like ceftazidime-avibactam
are preferred.
Page 4
Which statement best characterizes the structural basis for aztreonam's lack of
cross-reactivity in severe penicillin allergy while retaining gram-negative
activity?
A. Its beta-lactam ring is fused to a dihydrothiazine ring, unlike
penicillins.
B. It is a monobactam with a monocyclic beta-lactam nucleus and unique
side chains that avoid IgE recognition.
C. It lacks a beta-lactam ring entirely, so it cannot act as a hapten.
D. It is a carbapenem with a trans-configured hydroxyethyl side chain
that blocks beta-lactamase.
Correct Answer: B - It is a monobactam with a monocyclic
beta-lactam nucleus and unique side chains that avoid IgE
recognition.
RATIONALE
Aztreonam is a monobactam with a monocyclic beta-lactam ring and
distinct R-groups, minimizing cross-reactivity with penicillin IgE.
Option A describes cephalosporins (dihydrothiazine ring). Option C is
false; aztreonam has a beta-lactam ring. Option D describes
carbapenems' resistance mechanism, not aztreonam.
Question 2
A patient with a documented severe cephalosporin allergy (anaphylaxis to
ceftriaxone) requires empiric coverage for a complicated intra-abdominal
infection. Which regimen is most appropriate?
A. Cefepime plus metronidazole
B. Meropenem
C. Aztreonam plus metronidazole
D. Ceftazidime-avibactam
Correct Answer: C - Aztreonam plus metronidazole
Page 2
, RATIONALE
Aztreonam plus metronidazole provides gram-negative and anaerobic
coverage without cross-reactivity risk in severe cephalosporin allergy.
Cefepime and ceftazidime-avibactam are cephalosporins and
contraindicated. Meropenem, though structurally distinct, carries a
small cross-reactivity risk and is often avoided when a safe alternative
exists.
Question 3
Which pharmacodynamic parameter best predicts the efficacy of meropenem,
and how should dosing be adjusted to optimize it?
A. Peak concentration/MIC; give as a single large dose.
B. Time above MIC; use prolonged or continuous infusion.
C. AUC/MIC; use once-daily dosing.
D. Post-antibiotic effect; dose every 48 hours.
Correct Answer: B - Time above MIC; use prolonged or
continuous infusion.
RATIONALE
Carbapenems exhibit time-dependent killing, so the percentage of time
free drug exceeds MIC (%fT>MIC) correlates with efficacy;
prolonged/continuous infusion maximizes this. Option A describes
concentration-dependent killing (e.g., aminoglycosides). Option C
describes vancomycin dosing. Option D is not a primary PD parameter
for carbapenems.
Question 4
A patient receiving IV vancomycin develops flushing, pruritus, and
hypotension within 30 minutes of infusion start. Which mechanism best
explains this reaction?
A. IgE-mediated type I hypersensitivity
B. Direct mast cell degranulation (non-immune)
Page 3
, C. Immune complex deposition (type III)
D. T-cell mediated delayed hypersensitivity (type IV)
Correct Answer: B - Direct mast cell degranulation (non-immune)
RATIONALE
Vancomycin infusion reaction (formerly 'red man syndrome') is caused
by direct, non-immune mast cell degranulation and histamine release,
often rate-related. Type I IgE reactions are less common and typically
require prior sensitization. Type III and IV are not consistent with this
acute, infusion-related presentation.
Question 5
Which statement accurately distinguishes the activity of ceftazidime-avibactam
from that of meropenem against Klebsiella pneumoniae carbapenemase
(KPC)-producing organisms?
A. Meropenem is preferred because KPC enzymes do not hydrolyze
carbapenems.
B. Ceftazidime-avibactam is active because avibactam inhibits KPC,
whereas meropenem is hydrolyzed.
C. Both agents are equally active; choice depends only on allergy history.
D. Ceftazidime-avibactam is inactive against KPC; only colistin retains
activity.
Correct Answer: B - Ceftazidime-avibactam is active because
avibactam inhibits KPC, whereas meropenem is hydrolyzed.
RATIONALE
Avibactam is a diazabicyclooctane beta-lactamase inhibitor that
inhibits KPC and other serine carbapenemases, restoring ceftazidime
activity. Meropenem is hydrolyzed by KPC. Option A is false; KPC
hydrolyzes carbapenems. Option C is incorrect because activity
differs. Option D is outdated; newer agents like ceftazidime-avibactam
are preferred.
Page 4
